Biofrontera AG - Product Pipeline Review - 2012

Global Markets Direct, August 2012, Pages: 47

Biofrontera AG – Product Pipeline Review – 2012

Summary

Global Markets Direct’s pharmaceuticals report, “Biofrontera AG - Product Pipeline Review - 2012” provides data on the Biofrontera AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Biofrontera AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Biofrontera AG and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Biofrontera AG - Brief Biofrontera AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Biofrontera AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Biofrontera AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Biofrontera AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Biofrontera AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Biofrontera AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Biofrontera AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Biofrontera AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Biofrontera AG and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Biofrontera AG; Biofrontera AG - Key Therapeutics; Biofrontera AG - Pipeline Overview and Promising Molecules; Biofrontera AG - News; Biofrontera AG - Latest Updates; Biofrontera AG - Pipeline; Biofrontera AG - Discontinued/Dormant Projects

2
List of Tables 4
List of Figures 4
Biofrontera AG Snapshot 5
Biofrontera AG Overview 5
Key Information 5
Key Facts 5
Biofrontera AG – Research and Development Overview 6
Key Therapeutic Areas 6
Biofrontera AG – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Biofrontera AG – Pipeline Products Glance 10
Biofrontera AG Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Biofrontera AG – Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Biofrontera AG – Drug Profiles 13
Ameluz 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
BF-1 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
BF-derm1 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
BF-PC/13 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
BF-PC/18 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
BF-PC/21 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Biofrontera AG – Pipeline Products by Route of Administration 21
Biofrontera AG – Pipeline Products By Mechanism of Action 22
Biofrontera AG – Recent Pipeline Updates 23
Biofrontera AG - Dormant Projects 24
Biofrontera AG – Locations And Subsidiaries 25
Head Office 25
Biofrontera AG, Recent Developments 26
Biofrontera AG- Press Release 26
Jul 23, 2012: Biofrontera Discusses Approval Of Ameluz In US With FDA 26
Dec 02, 2009: Biofrontera Reports Preliminary Phase III Trial Results With BF-200 ALA 27
Nov 26, 2009: Biofrontera AG Announces Database Closure In Biofrontera's Phase III Trial With BF-200 ALA 27
Oct 08, 2009: Biofrontera Launches Belixos In Germany 28
Jul 27, 2009: Biofrontera Announces Phase II Clinical Trial Study Of BF-derm1 In Chronic Urticaria 28
Apr 29, 2009: Excellent Phase III Results Of Biofrontera’s BF-200 ALA Presented At Dermatology CongressA 29
Jan 29, 2009: Biofrontera Completes Patient Enrollment In Phase III Study With BF-200 ALA 29
Financial Deals Landscape 31
Biofrontera AG, Deals Summary 31
Biofrontera AG, Pharmaceuticals & Healthcare, Deal Details 32
Asset Transactions 32
Biofrontera Acquires Rights Of Relieva From Canadian Prime Pharma 32
Partnerships 34
Biofrontera Pharma Enters Into Co-Marketing Agreement With Bipharma For Ameluz 34
Biofrontera Pharma Enters Into Co-Marketing Agreement With Allergan For Ameluz 35
Biofrontera Enters Into Co-Marketing Agreement With Desitin For Ameluz 37
Biofrontera Enters Into Co-Marketing Agreement With DSE Healthcare Solutions 38
Equity Offering 39
Biofrontera Completes Rights Offering For $2.9 Million 39
Biofrontera Completes Private Placement Of $1.46 Million 41
Biofrontera Completes Rights Offering Of $4 Million 43
Biofrontera Completes Private Placement Of $0.66 Million 44
Biofrontera Completes Private Placement of $8.5 Million 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Biofrontera AG, Key Information 5
Biofrontera AG, Key Facts 5
Biofrontera AG – Pipeline by Indication, 2012 7
Biofrontera AG – Pipeline by Stage of Development, 2012 8
Biofrontera AG – Monotherapy Products in Pipeline, 2012 9
Biofrontera AG – Phase II, 2012 10
Biofrontera AG – Phase I, 2012 11
Biofrontera AG – Pre-Clinical, 2012 12
Biofrontera AG – Pipeline By Route of Administration, 2012 21
Biofrontera AG – Pipeline Products By Mechanism of Action, 2012 22
Biofrontera AG – Recent Pipeline Updates, 2012 23
Biofrontera AG - Dormant Developmental Projects,2012 24
Biofrontera AG, Deals Summary 31
Biofrontera Acquires Rights Of Relieva From Canadian Prime Pharma 32
Biofrontera Pharma Enters Into Co-Marketing Agreement With Bipharma For Ameluz 34
Biofrontera Pharma Enters Into Co-Marketing Agreement With Allergan For Ameluz 35
Biofrontera Enters Into Co-Marketing Agreement With Desitin For Ameluz 37
Biofrontera Enters Into Co-Marketing Agreement With DSE Healthcare Solutions 38
Biofrontera Completes Rights Offering For $2.9 Million 39
Biofrontera Completes Private Placement Of $1.46 Million 41
Biofrontera Completes Rights Offering Of $4 Million 43
Biofrontera Completes Private Placement Of $0.66 Million 44
Biofrontera Completes Private Placement of $8.5 Million 45

List of Figures
Biofrontera AG – Pipeline by Indication, 2012 7
Biofrontera AG – Pipeline by Stage of Development, 2012 8
Biofrontera AG – Monotherapy Products in Pipeline, 2012 9
Biofrontera AG – Pipeline By Route of Administration, 2012 21
Biofrontera AG - Pipeline Products By Mechanism of Action, 2012 22

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• eBay - Strong Execution
• Amazon - Point of Realization in 2013?
• Scientific Games Corporation - Company Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• SunGard - Profile - US
• Ixia - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model
• US - Accenture - Company Profile